151 related articles for article (PubMed ID: 37247396)
1. Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19.
Zeng G; Wang L; Li J; Zhang Z
J Med Virol; 2023 Jun; 95(6):e28836. PubMed ID: 37247396
[No Abstract] [Full Text] [Related]
2. Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: A retrospective cohort study.
Deng G; Li D; Sun Y; Jin L; Zhou Q; Xiao C; Wu Q; Sun H; Dian Y; Zeng F; Pan P; Shen M
J Med Virol; 2023 Apr; 95(4):e28756. PubMed ID: 37185838
[TBL] [Abstract][Full Text] [Related]
3. Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter retrospective cohort study.
Han X; Gao D; Li C; Yuan X; Cui J; Zhao W; Xie F; Wang K; Liu Y; Muo G; Xi N; Zheng M; Wang R; Xiao K; Zhao D; Zhang X; Han X; Wang B; Zhang T; Xie W; Xie L
BMC Infect Dis; 2024 Jan; 24(1):57. PubMed ID: 38191304
[TBL] [Abstract][Full Text] [Related]
4. Azvudine and nirmatrelvir-ritonavir in hospitalized patients with moderate-to-severe COVID-19: Emulation of a randomized target trial.
Zhou Y; Liu Y; Jiang L; Zhang R; Zhang H; Shi Q; Yang Z; Mao Y; Liu S; Yang Z; Ding J; Zhou Y; Ren B; He L; Zhao X; Li W; Li S; Liu D
J Med Virol; 2023 Dec; 95(12):e29318. PubMed ID: 38112106
[TBL] [Abstract][Full Text] [Related]
5. Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study.
Chen MP; Jiang DX; Rang JX; Zhuo HB; Zhou ZG
Sci Rep; 2024 Feb; 14(1):3318. PubMed ID: 38337014
[TBL] [Abstract][Full Text] [Related]
6. Antiviral effect of azvudine and nirmatrelvir-ritonavir among hospitalized patients with COVID-19.
Gao Y; Luo Z; Ren S; Duan Z; Han Y; Liu H; Gao Z; Zhang X; Hu Z; Ma Y
J Infect; 2023 Jun; 86(6):e158-e160. PubMed ID: 37003523
[No Abstract] [Full Text] [Related]
7. Head-to-head comparison of azvudine and nirmatrelvir/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching.
Wei AH; Zeng L; Wang L; Gui L; Zhang WT; Gong XP; Li J; Liu D
Front Pharmacol; 2023; 14():1274294. PubMed ID: 37900159
[No Abstract] [Full Text] [Related]
8. Effectiveness and safety of azvudine in older adults with mild and moderate COVID-19: a retrospective observational study.
Zhou Z; Zheng H; Xiao G; Xie X; Rang J; Peng D
BMC Infect Dis; 2024 Jan; 24(1):47. PubMed ID: 38177982
[TBL] [Abstract][Full Text] [Related]
9. Antiviral effectiveness and survival correlation of azvudine and nirmatrelvir/ritonavir in elderly severe patients with COVID-19: a retrospective real-world study.
Wang S; Sun J; Zhang X; Li M; Qin B; Liu M; Zhang N; Wang S; Zhou T; Zhang W; Ma C; Deng X; Bai Y; Qu G; Liu L; Shi H; Zhou B; Li K; Yang B; Li S; Wang F; Ma J; Zhang L; Wang Y; An L; Liu W; Chang Q; Zhang R; Yin X; Yang Y; Ao Q; Ma Q; Yan S; Huang H; Song P; Gao L; Lu W; Xu L; Lei L; Wang K; Zhang Q; Song Q; Zhang Z; Fang X; He Y; Li T; Zhu P
EClinicalMedicine; 2024 Mar; 69():102468. PubMed ID: 38361990
[TBL] [Abstract][Full Text] [Related]
10. Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study.
Zhao Q; Zheng B; Han B; Feng P; Xia Z; Jiang H; Ying Y; Zhu J; Fei C; Xiang J; Shen L; Luo Q; Wu Y; Wusiman A; Xin C; Zhang M; Li G; Li X
Infect Dis Ther; 2023 Aug; 12(8):2087-2102. PubMed ID: 37486556
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19.
Focosi D; Nicastri E
Ann Intern Med; 2023 Oct; 176(10):eL230264. PubMed ID: 37844308
[No Abstract] [Full Text] [Related]
12. Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19.
Wan EYF; Yan VKC; Mok AHY; Wong ICK; Chan EWY
Ann Intern Med; 2023 Oct; 176(10):eL230265. PubMed ID: 37844307
[No Abstract] [Full Text] [Related]
13. Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study.
Zhao X; Cheng Y; Zhang M; Qianda B; Zhouma B; Yangzhen B; Zheng Y; Zhang S; Zhao H
Infect Drug Resist; 2023; 16():6053-6060. PubMed ID: 37719651
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Azvudine and Nirmatrelvir/Ritonavir and Combined Use in Patients with COVID-19.
Hu CY; Cui WS; Lei Y; Tang YW; Zhang YY; Su QM; Peng F; Zeng YF; Song JL; Luo CN; Zhou Y; Li XY; Zhao ZX
Infect Drug Resist; 2023; 16():7797-7808. PubMed ID: 38148771
[TBL] [Abstract][Full Text] [Related]
15. Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19.
Sutanto ST; Sinto R; Pasaribu A; Shakinah S
Acta Med Indones; 2022 Oct; 54(4):638-644. PubMed ID: 36624705
[TBL] [Abstract][Full Text] [Related]
16. Clinical Outcomes Following Treatment for COVID-19 With Nirmatrelvir/Ritonavir and Molnupiravir Among Patients Living in Nursing Homes.
Ma BH; Yip TC; Lui GC; Lai MS; Hui E; Wong VW; Tse YK; Chan HL; Hui DS; Kwok TC; Wong GL
JAMA Netw Open; 2023 Apr; 6(4):e2310887. PubMed ID: 37103932
[TBL] [Abstract][Full Text] [Related]
17. Association of Molnupiravir and Nirmatrelvir-Ritonavir with reduced mortality and sepsis in hospitalized omicron patients: a territory-wide study.
Wai AK; Lee TT; Chan SC; Chan CY; Yip ET; Luk LY; Ho JW; So KW; Tsui OW; Lam ML; Lee SY; Yamamoto T; Tong CK; Wong MS; Wong EL; Rainer TH
Sci Rep; 2023 May; 13(1):7832. PubMed ID: 37188726
[TBL] [Abstract][Full Text] [Related]
18. Clinical Effectiveness of Nirmatrelvir plus Ritonavir in the Treatment of COVID-19 for Patients With Dementia.
Liu TH; Hsu WH; Tsai YW; Wu JY; Huang PY; Chuang MH; Lai CC
J Am Med Dir Assoc; 2023 Aug; 24(8):1159-1162. PubMed ID: 37423261
[No Abstract] [Full Text] [Related]
19. The Antiviral Effect of Nirmatrelvir/Ritonavir during COVID-19 Pandemic Real-World Data.
Petrakis V; Rafailidis P; Trypsianis G; Papazoglou D; Panagopoulos P
Viruses; 2023 Apr; 15(4):. PubMed ID: 37112956
[TBL] [Abstract][Full Text] [Related]
20. Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.
Saravolatz LD; Depcinski S; Sharma M
Clin Infect Dis; 2023 Jan; 76(1):165-171. PubMed ID: 35245942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]